Alcolase
Develops enzyme-based biotechnology treatments intended to help people manage alcohol intolerance and related reactions.
Overview
Alcolase is a biotechnology company developing an enzyme treatment for alcohol intolerance. Its work targets people who experience adverse reactions to alcohol, positioning the company in a health-focused deep tech niche rather than an AI market. The company’s stated differentiator is an enzyme-based approach to addressing alcohol intolerance. Funding records show €2M raised across one round, with Ada Ventures and Antler named as backers in a May 2026 round described as €1.5M.
Funding History
Ada Ventures, Antler back Alcolase in €1.5M round to develop enzyme treatment for alcohol intolerance
Frequently Asked Questions
- How much funding does AI Funding track for Alcolase?
- AI Funding tracks €2M for Alcolase across 1 funding round in this database.
- Who are Alcolase's investors?
- Alcolase's investors include Antler, Ada Ventures, Delphinus Venture Capital, Manigoff Invest.
- What does Alcolase do?
- Alcolase is a biotechnology company developing an enzyme treatment for alcohol intolerance. Its work targets people who experience adverse reactions to alcohol, positioning the company in a health-focused deep tech niche rather than an AI market. The company’s stated differentiator is an enzyme-based approach to addressing alcohol intolerance. Funding records show €2M raised across one round, with Ada Ventures and Antler named as backers in a May 2026 round described as €1.5M.
- Where is Alcolase headquartered?
- Alcolase is headquartered in San Francisco, CA.
Investors
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.